NLS drug-2

The company has announced data from a non-clinical study exploring 177Lu-SN201 in a model for triple-negative breast cancer. In the model, 177Lu-SN201 demonstrates superior anti-tumor effect compared to standard cancer drugs with a low and acceptable level of radiotoxicity observed, states the company. “Triple-negative breast cancer is a very aggressive disease with poor prognosis. The […]

The company has announced the initiation of the Phase 2 clinical trial VB-C-04. The trial evaluates VB10.16, the company’s off-the-shelf therapeutic cancer vaccine candidate for HPV16-positive cancers, alone or in combination with Roche’s checkpoint inhibitor atezolizumab (Tecentriq) in patients with HPV16positive, PD-L1-positive, recurrent, or metastatic cervical cancer. “Initiating the VB10.16 trial for HPV16-positive cervical cancer […]

TILT Biotherapeutics has presented preliminary safety and efficacy data from their ongoing Phase I clinical trial in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024. “We are excited to see the latest ongoing positive potential to bring a more effective treatment to patients with refractory […]

Elypta has announced that the interim results from the LEVANTIS-0087A study will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego during the Biomarker-Based Screening session on April 9. The population-based case-control study included 2,054 adults over the age of 18 with no symptoms of cancer from the […]

Affibody has announced that the first patients have been dosed in a clinical basket study of the PET imaging agent 68Ga-ABY-025 for non-invasive quantification of HER2-status in solid tumors. ABY-025 is based on an Affibody molecule that binds strongly to HER2 – a cell surface protein implicated in several forms of cancer. The high affinity […]

Sobi has announced results from the AVA-PED-301 study, evaluating the efficacy and safety of avatrombopag (Doptelet) for the treatment of paediatric patients with immune thrombocytopenia (ITP) of at least 6 months’ duration. The study enrolled 75 subjects between 1 and <18 years and the primary endpoint, durable platelet response, was met in 28% of avatrombopag […]